TITLE: Best Practice for Management of Ulcerative Colitis and its Complications: Clinical Evidence and Guidelines

DATE: 14 June 2011

RESEARCH QUESTIONS

1. What is the clinical evidence on the treatment of ulcerative colitis and the complications of ulcerative colitis, including toxic megacolon?

2. What are the evidence-based guidelines for the treatment of ulcerative colitis and the complications of ulcerative colitis, including toxic megacolon?

KEY MESSAGE

The literature suggests that various pharmacological, medical or surgical treatment options may be effective for the treatment of ulcerative colitis and its complications.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2011, Issue 5), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between Jan 1, 2008 and Jun 2, 2011. Internet links were provided, where available.

The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article.
RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by evidence-based guidelines.

Twelve systematic reviews and meta-analyses and three evidence-based guidelines were identified regarding the treatment of ulcerative colitis and the complications of ulcerative colitis, including toxic megacolon, were identified. No relevant health technology assessments were identified. Due to the large volume of relevant literature, systematic reviews included in the main body of the report were limited to those examining multiple drug therapies, or surgical or medical procedure options. Systematic reviews and meta-analyses looking at single drug treatments have been included in the appendix. Randomized controlled trials were limited to those regarding surgical or medical procedure options and those studies whose outcomes included the prevention of those interventions. Additional articles that may be of interest are also available in the appendix.

OVERALL SUMMARY OF FINDINGS

The results of 12 systematic reviews and meta-analyses\footnote{1-12} examining drug therapies and surgical and medical procedure options are summarized in Table 1. Treatments that were deemed to be effective for UC included low molecular weight heparin colon-release tablets,\footnote{1} glucocorticosteroids,\footnote{2} antibiotics,\footnote{3} immunosuppressive therapies,\footnote{4,8} probiotics,\footnote{5} 5-aminosalicylates,\footnote{8} selective leukocytapheresis,\footnote{10} and granulocyte/monocyte adsorptive apheresis.\footnote{11}

<table>
<thead>
<tr>
<th>Table 1: Summary of Included Systematic Reviews and Meta-Analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authors</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td><strong>Drug therapies</strong></td>
</tr>
<tr>
<td>Chande et al.\footnote{1}</td>
</tr>
<tr>
<td>Ford et al.\footnote{5}</td>
</tr>
<tr>
<td>Khan et al.\footnote{3}</td>
</tr>
<tr>
<td>Khan et al.\footnote{4}</td>
</tr>
</tbody>
</table>
### Table 1: Summary of Included Systematic Reviews and Meta-Analyses

<table>
<thead>
<tr>
<th>Authors</th>
<th>Interventions</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sang et al.</td>
<td>Probiotics for remission and maintenance of UC</td>
<td>The authors determined probiotic treatment, including <em>Bifidobacterium bifidum</em>, was more effective than placebo for remission maintenance in UC.</td>
</tr>
<tr>
<td>Gisbert et al.</td>
<td>Thiopurines (azathioprine and mercaptopurine) for</td>
<td>Mean efficacy of the treatment was 65% for induction of remission and 76% for maintenance of remission. The authors concluded thiopurines were more effective than placebo for prevention of relapse of UC.</td>
</tr>
<tr>
<td>Nikfar et al.</td>
<td>Sulfaaltazine versus 5-ASAs for improvement and</td>
<td>Sulfaaltazine did not differ from 5-ASAs in respect to efficacy and tolerability in UC. The authors suggest sulfaaltazine as a first-line treatment and recommend the use of 5-ASAs when sulfaaltazine is not tolerated.</td>
</tr>
<tr>
<td>Rahimi et al.</td>
<td>5-ASAs (mesalazine versus balsalazide) for</td>
<td>5-ASAs are the standard treatment in mild-to-moderate UC. The authors concluded that balsalazide was more effective than mesalazine for remission, but it had no benefit over mesalazine for the prevention of relapse.</td>
</tr>
<tr>
<td>Seow et al.</td>
<td>Type I IFNs for induction of remission in UC</td>
<td>There was no significant benefit for type I IFNs over placebo for the induction of remission of UC.</td>
</tr>
</tbody>
</table>

#### Surgical or medical procedure options

<table>
<thead>
<tr>
<th>Authors</th>
<th>Interventions</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhu et al.</td>
<td>Selective leukocytapheresis for treatment of UC</td>
<td>Selective leukocytapheresis as supplemental therapy was compared with conventional pharmacotherapy. The authors concluded leukocytapheresis supplementation provided a significant benefit to response and remission rates and significantly higher steroid-sparing rates.</td>
</tr>
<tr>
<td>Thanaraj et al.</td>
<td>GMMA for UC</td>
<td>GMMA was compared with conventional medical therapy, sham procedures, or intensive GMAA. Remission rates with GMMA were generally higher than with conventional therapy and steroid-sparing effects were observed. Compared to sham procedures, GMMA did not achieve higher remission rates. Intensive GMAA regimens had higher remission rates. The authors concluded that GMMA may have some benefit for the treatment of UC.</td>
</tr>
<tr>
<td>Teeuwen et al.</td>
<td>Colectomy for severe acute UC</td>
<td>Studies were identified that described patients operated on in an acute setting. Over three decades, there was a shift in prevalence from toxic megacolon to severe acute colitis not responding to conservative treatment. Considerable morbidity was associated with colectomy.</td>
</tr>
</tbody>
</table>

ASA = aminosalicylates; GMMA = granulocyte/monocyte adsorptive apheresis; LMWH = low molecular weight heparin; IFNs = interferons; UC = ulcerative colitis; UFH = unfractionated heparin

Three evidence-based guidelines\textsuperscript{13-15} were identified regarding the treatment of ulcerative colitis. For the management of UC, the guidelines\textsuperscript{14,15} suggest dietary and lifestyle changes may help to reduce symptoms. Pharmacotherapy may include aminosalicylates (anti-inflammatory agents), corticosteroids, and immune modifiers such as antibiotics and probiotics. Surgical treatment options include temporary ileostomy, total proctocolectomy plus permanent ileostomy, and ileal pouch–anal anastomosis. For the management of toxic megacolon, one guideline\textsuperscript{15} recommends “all patients with severe acute colitis and signs of colonic distension should have daily abdominal radiographs to monitor for toxic megacolon, until there is clinical and radiological improvement or the decision has been made to perform a colectomy.”
Guidelines prepared by the American College of Gastroenterology and its Practice Parameters Committee were identified, however, no information relating to the content or recommendations were provided within the abstract.
REFERENCES SUMMARIZED

Health technology assessments
No literature identified.

Systematic reviews and meta-analyses

Drug therapies


   PubMed: PM18646167

Surgical or medical procedure options

    PubMed: PM21476027

    PubMed: PM21050231

    PubMed: PM19132451

Guidelines and recommendations

    PubMed: PM20068560


    See: Findings and Recommendations, page 15

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Systematic reviews and meta-analyses – single drug reviews


Randomized controlled trials


Review articles


Additional references

